Agenda & Learning Objectives

 

Participants in this program will be able to:

  • Explore advances in IBD therapeutics 
    • Apply analytic techniques to compare safety and efficacy of drugs in practice
    • Review data on comparative efficacy and safety of currently available biologics
    • Summarize research development in treatment of IBD with JAK inhibitors and other novel small molecules
  • Examine nutrition and nutritional support in IBD
    • Appraise dietary therapy in IBD
    • Discuss iron deficiency in IBD
  • Integrate basic science and clinical practice by participation in a choice of workshop to:
    • Review therapeutics for multiple immune-mediated disorders, or
    • Examine iron therapy management in the IBD patient, or
    • Discuss dietary strategies in the management of Crohn’s disease and ulcerative colitis, or
    • Reflect on the treatment of IBD with biologics during pregnancy
  • Discuss mechanisms and outcomes in IBD
    • Consider drug-induced colitis and what we can learn about IBD pathogenesis
    • Identify new endpoints in IBD with a view to the future
Time Title/Topic Speakers
08:30 Welcome: Nurse of the Year Award, Physician of the Year Award Mina Mawani, CCC CEO
08:45 Opening Remarks
CO-CHAIRS:
Remo Panaccione &
Hillary Steinhart

Session I: Advances in Therapeutics in IBD

SESSION CHAIR:
Hillary Steinhart
08:55 Plenary Presentation
1.1 Clinical Research Methodology
The goal of this session is not to review the results of individual studies or the meaning of the data, but to describe how these analytic techniques are applied so as to give delegates the tools to examine the literature and analyze the results to take into consideration in their practice.
Session Objectives:
  • Discuss different methods of comparison 
    • How do you compare efficacy and safety of drugs?
    • What are the methods?
  • Meta-analysis, network analysis, uncontrolled cohorts, superiority, non-inferiority studies, propensity analysis
    • Discuss the advantages/disadvantage of each and how to approach the evidence
  • Discuss the different designs that compare efficacy and safety across the drugs
Christopher Ma
University of Calgary
09:15 Plenary Presentation
1.2 Comparative Efficacy and Safety of Biologics
Session Objectives:
  • Review the data on comparative efficacy of currently available biologics
  • Review the data on comparative safety of currently available biologics
  • Discuss biomarkers of response or non-response that may help clinicians choose in future
Brian Feagan
Western University
09:35 Plenary Presentation
1.3 JAK Inhibitors and the Next Wave of Oral Small Molecules in the Management of IBD
Session Objectives:
  • Describe the relationship between the JAK-STAT signaling pathway and pathogenesis of IBD
  • Summarize the latest research developments in treatment of IBD with JAK inhibitors
  • Review the latest data in other novel small molecules
Remo Panaccione
University of Calgary
09:55 Ask-the Expert Panel Session SESSION CHAIR: Hillary Steinhart
PANEL: Brian Fegan, Christopher Ma, Remo Panaccione
10:15 Plenary Presentation
1.4 Meeting of the Minds Junior Investigator Award Presentation
TBA
10:35
Refreshment Break
 

Session II: Nutrition and Nutrional Support in IBD

SESSION CHAIR:
Anne Griffiths
10:50 Plenary Presentation
2.1 Dietary Therapy in IBD: What is the rationale? Does it work?
Session Objectives:
  • Consider potential mechanisms of action of dietary therapy in IBD
  • Examine predictors of response to diet and dietary factors rather than trials that put people on a diet and look at clinical outcomes
  • Reflect on patient types or predictors of response to diet therapy in IBD
Eytan Wine
University of Alberta
11:10 Plenary Presentation
2.2 Iron Deficiency in IBD
Session Objectives:
  • Discuss iron absorption and metabolism and the impact of IBD
  • Review impact of iron deficiency on quality of life in IBD both with and without associated anemia
  • Review newer iron products, both oral and intravenous including efficacy and safety
Christoph Gasche
Medical University of Vienna
11:30 Ask-the Expert Panel Session SESSION CHAIR: Anne Griffiths
PANEL: Christoph Gasche, Eytan Wine
11:50
Plenary Presentation
2.3 Rising Star Award Plenary Presentation
MODERATOR: Mina Mawani
TBA
12:10
Lunch
 

Session III: Workshops – Hot Topics from Bed to Bench to Policy
(Delegates attend choice of one 45-minute workshop)

13:05 Workshop
3.1 Therapeutics for Multiple Immune-Mediated Disorders
Session Objectives:
  • Consider when you would consider combination biologic therapy for a patient with multiple autoimmune diseases
  • Discuss how to assess and manage safety issues in combination biologic therapy
  • Explain what the existing research literature can tell us about combining therapy for patients with multiple immune-mediated disorders
Jennifer Jones
Dalhousie University

Christopher Ma
University of Calgary
Workshop
3.2 Iron Therapy Management in the IBD Patient
Session Objectives: 
  • Review basic physiology of iron absorption
  • Describe the effect of iron on oxidative stress
  • Discuss considerations in clinical care
Christoph Gasche
Medical University of Vienna

Thomas Walters
University of Toronto
Workshop
3.3 Dietary Strategies in IBD (UC and CD)
Session Objectives:
  • Examine dietary interventions that are appropriate in different clinical situations
  • Review the approach to assessment of nutritional status in the IBD patient
Melanie Stapleton
University of Calgary

Eytan Wine
University of Alberta
Workshop:
3.4 Treating IBD During Pregnancy: Focus on Biologics
Session Objectives:
  • Demonstrate peripartum counselling in patients with IBD
  • Discuss the safety of biologic therapy in pregnancy
Daniel Baumgart
University of Alberta

Vivian Huang
University of Toronto

Session IV: New Eyes on Mechanisms and Outcomes in IBD

SESSION CHAIR:
Andrew Stadnyk
14:00 4.0 Research Leadership Award & Presentation MODERATOR: Mina Mawani
TBA
14:20 Plenary Presentation
4.1 Drug-Induced Colitis and What We Can Learn About IBD Pathogenisis
Session Objectives:
  • Describe the mechanism of checkpoint inhibitor-induced colitis
    • Tie in EIMs on basic level
  • Explain mechanistic perspective on non-IBD immune-mediated colidites
  • Review NSAID-induced colitis
  • Discuss mechanism and immune-mediated conditions that you can get with checkpoint inhibitors
Paul Beck
University of Calgary
14:40 Plenary Presentation
4.2 New Endpoints in IBD: What will the future look like?
Session Objectives:
  • Discuss why new endpoints are needed in IBD trials
  • Demonstrate evidence for the development of new endpoints
Vipul Jairath
Western University
15:00 4.3 Ask-the-Expert Panel Session SESSION CHAIR: Andrew Stadnyk
PANEL: Paul Beck, Vipul Jairath
15:20 Closing Remarks and Program Evaluation CO-CHAIRS:
Remo Panaccione &
Hillary Steinhart

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.